OBJECTIVES: The aim of this study was to evaluate whether transcatheter aortic valve replacement (TAVR) with the SAPIEN 3 valve (S3-TAVR) results in improved quality of life (QoL) compared with previous-generation TAVR devices or surgical aortic valve replacement (SAVR). BACKGROUND: In patients with severe aortic stenosis at intermediate surgical risk, TAVR using the SAPIEN XT valve (XT-TAVR) results in similar QoL compared with SAVR. Compared with SAPIEN XT, the SAPIEN 3 valve offers a lower delivery profile and modifications to reduce paravalvular regurgitation. METHODS: Between February and December 2014, 1,078 patients at intermediate surgical risk with severe aortic stenosis were treated with S3-TAVR in the PARTNER S3i (Placement of Aortic Transcatheter Valve) trial. QoL was assessed at baseline, 1 month, and 1 year using the Kansas City Cardiomyopathy Questionnaire, Medical Outcomes Study Short Form-36, and EQ-5D. QoL outcomes of S3-TAVR patients were compared with those in the SAVR and XT-TAVR arms of the PARTNER 2A trial using propensity score stratification to adjust for differences between the treatment groups. RESULTS: Over 1 year, S3-TAVR was associated with substantial improvements in QoL compared with baseline. At 1 month, S3-TAVR was associated with better QoL than either SAVR or XT-TAVR (adjusted differences in Kansas City Cardiomyopathy Questionnaire overall summary score 15.6 and 3.7 points, respectively; p < 0.001). At 1 year, the differences in QoL between S3-TAVR and both SAVR and XT-TAVR were reduced but remained statistically significant (adjusted differences 2.0 and 2.2 points, respectively; p < 0.05). Similar results were seen for generic QoL outcomes. CONCLUSIONS: Among patients at intermediate surgical risk with severe aortic stenosis, S3-TAVR resulted in improved QoL at both 1 month and 1 year compared with both XT-TAVR and SAVR.
OBJECTIVES: The aim of this study was to evaluate whether transcatheter aortic valve replacement (TAVR) with the SAPIEN 3 valve (S3-TAVR) results in improved quality of life (QoL) compared with previous-generation TAVR devices or surgical aortic valve replacement (SAVR). BACKGROUND: In patients with severe aortic stenosis at intermediate surgical risk, TAVR using the SAPIEN XT valve (XT-TAVR) results in similar QoL compared with SAVR. Compared with SAPIEN XT, the SAPIEN 3 valve offers a lower delivery profile and modifications to reduce paravalvular regurgitation. METHODS: Between February and December 2014, 1,078 patients at intermediate surgical risk with severe aortic stenosis were treated with S3-TAVR in the PARTNER S3i (Placement of Aortic Transcatheter Valve) trial. QoL was assessed at baseline, 1 month, and 1 year using the Kansas City Cardiomyopathy Questionnaire, Medical Outcomes Study Short Form-36, and EQ-5D. QoL outcomes of S3-TAVRpatients were compared with those in the SAVR and XT-TAVR arms of the PARTNER 2A trial using propensity score stratification to adjust for differences between the treatment groups. RESULTS: Over 1 year, S3-TAVR was associated with substantial improvements in QoL compared with baseline. At 1 month, S3-TAVR was associated with better QoL than either SAVR or XT-TAVR (adjusted differences in Kansas City Cardiomyopathy Questionnaire overall summary score 15.6 and 3.7 points, respectively; p < 0.001). At 1 year, the differences in QoL between S3-TAVR and both SAVR and XT-TAVR were reduced but remained statistically significant (adjusted differences 2.0 and 2.2 points, respectively; p < 0.05). Similar results were seen for generic QoL outcomes. CONCLUSIONS: Among patients at intermediate surgical risk with severe aortic stenosis, S3-TAVR resulted in improved QoL at both 1 month and 1 year compared with both XT-TAVR and SAVR.
Authors: Suzanne V Arnold; John A Spertus; Yang Lei; Keith B Allen; Adnan K Chhatriwalla; Martin B Leon; Craig R Smith; Matthew R Reynolds; John G Webb; Lars G Svensson; David J Cohen Journal: Circ Heart Fail Date: 2012-12-10 Impact factor: 8.790
Authors: Matthew R Reynolds; Elizabeth A Magnuson; Kaijun Wang; Vinod H Thourani; Mathew Williams; Alan Zajarias; Charanjit S Rihal; David L Brown; Craig R Smith; Martin B Leon; David J Cohen Journal: J Am Coll Cardiol Date: 2012-07-18 Impact factor: 24.094
Authors: Michael J Reardon; David H Adams; Neal S Kleiman; Steven J Yakubov; Joseph S Coselli; G Michael Deeb; Thomas G Gleason; Joon Sup Lee; James B Hermiller; Stan Chetcuti; John Heiser; William Merhi; George L Zorn; Peter Tadros; Newell Robinson; George Petrossian; G Chad Hughes; J Kevin Harrison; Brijeshwar Maini; Mubashir Mumtaz; John V Conte; Jon R Resar; Vicken Aharonian; Thomas Pfeffer; Jae K Oh; Hongyan Qiao; Jeffrey J Popma Journal: J Am Coll Cardiol Date: 2015-06-05 Impact factor: 24.094
Authors: Michael J Reardon; Nicolas M Van Mieghem; Jeffrey J Popma; Neal S Kleiman; Lars Søndergaard; Mubashir Mumtaz; David H Adams; G Michael Deeb; Brijeshwar Maini; Hemal Gada; Stanley Chetcuti; Thomas Gleason; John Heiser; Rüdiger Lange; William Merhi; Jae K Oh; Peter S Olsen; Nicolo Piazza; Mathew Williams; Stephan Windecker; Steven J Yakubov; Eberhard Grube; Raj Makkar; Joon S Lee; John Conte; Eric Vang; Hang Nguyen; Yanping Chang; Andrew S Mugglin; Patrick W J C Serruys; Arie P Kappetein Journal: N Engl J Med Date: 2017-03-17 Impact factor: 91.245
Authors: Gabriel E Soto; Philip Jones; William S Weintraub; Harlan M Krumholz; John A Spertus Journal: Circulation Date: 2004-07-19 Impact factor: 29.690
Authors: Mikhail Kosiborod; Gabriel E Soto; Philip G Jones; Harlan M Krumholz; William S Weintraub; Prakash Deedwania; John A Spertus Journal: Circulation Date: 2007-04-09 Impact factor: 29.690
Authors: Vittal Hejjaji; David J Cohen; John D Carroll; Zhuokai Li; Pratik Manandhar; Sreekanth Vemulapalli; Adam J Nelson; Ali O Malik; Michael J Mack; John A Spertus; Suzanne V Arnold Journal: Circ Cardiovasc Qual Outcomes Date: 2021-02-18
Authors: V Lorenzoni; G Barbieri; F Saia; F Meucci; G L Martinelli; A G Cerillo; S Berti; P Candolfi; G Turchetti Journal: Eur J Health Econ Date: 2021-05-21